📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Paradigm

1.1 - Company Overview

Paradigm Logo

Paradigm

Headquarter: United States
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of cutting-edge molecular diagnostics and biomarker-driven clinical trials for cancer patients and industry, using Next-Gen Sequencing and other biomarker analysis to deliver information on the genomic and proteomic landscape of a patient's cancer and potential therapies based on specific characterization of the cancer.

Products and services

🔒

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Paradigm

RefleXion Logo

RefleXion

HQ: United States Website
  • Description: Provider of biologically-guided radiotherapy systems for patients with cancer, offering SCINTIX therapy that uses emissions from cancer cells to target and treat lung or bone tumors at any stage. Provides the RefleXion X1 platform delivering SCINTIX and CT-guided IMRT and SBRT with fan-beam kVCT imaging for superior patient localization, plus Limbus Contour integration to expedite radiotherapy planning.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full RefleXion company profile →
Ultivue Logo

Ultivue

HQ: United States Website
  • Description: Provider of tissue imaging and multiplex biomarker assay solutions for precision medicine research, including InSituPlex DNA-barcoded antibody technology, custom assay development, pre-optimized ready-to-use multiplex staining kits, specialized AI tools and full lifecycle image analysis for multiplex immunofluorescence, and OmniVUE customizable biomarker panel design kits.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Ultivue company profile →
CytomX Therapeutics Logo

CytomX Therapeutics

HQ: United States Website
  • Description: Provider of proteolytically activated Probody therapeutics designed to activate only in cancer via tumor-specific proteases, minimizing activity in healthy tissue. Pipeline includes CX-904, a T-cell-engaging bispecific Probody targeting EGFR and CD3 in Phase 1 for advanced solid tumors; CX-2051, a conditionally activated EpCAM-targeting antibody-drug conjugate; and CX-801, an interferon alpha-2b Probody.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full CytomX Therapeutics company profile →
Ceptaris Logo

Ceptaris

HQ: United States Website
  • Description: Provider of a proprietary gel formulation of mechlorethamine hydrochloride under development for the treatment of early-stage (stages I–IIA) mycosis fungoides, a type of cutaneous T-cell lymphoma (CTCL); if approved, it would be the first topical treatment for this indication.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Ceptaris company profile →
FocalRx Logo

FocalRx

HQ: United States Website
  • Description: Provider of novel tissue-marking devices for surgery that mark the surgical site of tissue removal in 3D. Its BioZorb tissue marker is an implantable device placed by surgeons to delineate the site of tissue removal and help surgeons, radiation oncologists, and other clinicians clearly identify the surgical site.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full FocalRx company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Paradigm

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Paradigm

2.2 - Growth funds investing in similar companies to Paradigm

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Paradigm

4.2 - Public trading comparable groups for Paradigm

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Paradigm

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Paradigm

What does Paradigm do?

Paradigm is a provider of cutting-edge molecular diagnostics and biomarker-driven clinical trials for cancer patients and industry, using Next-Gen Sequencing and other biomarker analysis to deliver information on the genomic and proteomic landscape of a patient's cancer and potential therapies based on specific characterization of the cancer.

Who are Paradigm's competitors?

Paradigm's competitors and similar companies include RefleXion, Ultivue, CytomX Therapeutics, Ceptaris, and FocalRx.

Where is Paradigm headquartered?

Paradigm is headquartered in United States.

How many employees does Paradigm have?

Paradigm has 1,000 employees 🔒.

When was Paradigm founded?

Paradigm was founded in 2010 🔒.

What sector and industry vertical is Paradigm in?

Paradigm is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Paradigm

Who are the top strategic acquirers in Paradigm's sector and industry

Top strategic M&A buyers and acquirers in Paradigm's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Paradigm?

Top strategic M&A buyers groups and sectors for Paradigm include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Paradigm's sector and industry vertical

Which are the top PE firms investing in Paradigm's sector and industry vertical?

Top PE firms investing in Paradigm's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Paradigm's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Paradigm's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Paradigm's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Paradigm include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Paradigm's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Paradigm?

The key public trading comparables and valuation benchmarks for Paradigm include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Paradigm for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Paradigm with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Paradigm's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Paradigm with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Paradigm's' sector and industry vertical?

Access recent funding rounds and capital raises in Paradigm's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Paradigm